Edition:
United Kingdom

Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

65.93USD
8:00pm GMT
Change (% chg)

$3.18 (+5.07%)
Prev Close
$62.75
Open
$63.53
Day's High
$66.13
Day's Low
$63.33
Volume
134,564
Avg. Vol
192,001
52-wk High
$99.77
52-wk Low
$41.63

Latest Key Developments (Source: Significant Developments)

Agios Reports Updated Data From Phase 1 Study Of Ivosidenib In Combination With Azacitidine
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS UPDATED DATA FROM PHASE 1 STUDY OF IVOSIDENIB IN COMBINATION WITH AZACITIDINE DEMONSTRATING DEEP AND DURABLE RESPONSES IN NEWLY DIAGNOSED IDH1 MUTANT ACUTE MYELOID LEUKEMIA (AML) PATIENTS.AGIOS PHARMACEUTICALS INC - OVERALL RESPONSE RATE OF 78%, CR+CRH RATE OF 65% AND 12-MONTH SURVIVAL RATE OF 82%.AGIOS PHARMACEUTICALS INC - MEAN NEUTROPHIL AND PLATELET COUNTS WERE MAINTAINED NEAR OR ABOVE CRH THRESHOLDS WHILE ON STUDY TREATMENT.AGIOS PHARMA - SAFETY PROFILE OF COMBINATION THERAPY REMAINS CONSISTENT WITH SAFETY PROFILE OF IVOSIDENIB AND AZACITIDINE ALONE IN PATIENT POPULATION.  Full Article

Agios Highlights Key 2019 Initiatives To Broaden Potential For Cancer And Rare Genetic Disease Programs
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS HIGHLIGHTS KEY 2019 INITIATIVES TO BROADEN POTENTIAL FOR CANCER AND RARE GENETIC DISEASE PROGRAMS TO BUILD LONG-TERM VALUE.AGIOS PHARMACEUTICALS - ENDED 2018 WITH ABOUT $805 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.AGIOS - EXPECTS CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF DEC 31, 2018 TO FUND ANTICIPATED OPERATING EXPENSES THROUGH AT LEAST END OF 2020.  Full Article

FDA Says Symptoms Of Differentiation Syndrome Are Not Being Recognized With Idhifa
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - U.S. Food and Drug Administration::FDA WARNS THAT SYMPTOMS OF A SERIOUS CONDITION AFFECTING THE BLOOD CELLS ARE NOT BEING RECOGNIZED WITH THE LEUKEMIA MEDICINE IDHIFA (ENASIDENIB).FDA - IDHIFA PRESCRIBING INFORMATION AND PATIENT MEDICATION GUIDE ALREADY CONTAIN A WARNING ABOUT DIFFERENTIATION SYNDROME..FDA - BECOME AWARE OF CASES OF DIFFERENTIATION SYNDROME IN PATIENTS RECEIVING IDHIFA NOT BEING RECOGNIZED, PATIENTS NOT RECEIVING NECESSARY TREATMENT.FDA - IDHIFA IS MANUFACTURED FOR AND MARKETED BY CELGENE, LICENSED FROM AGIOS PHARMACEUTICALS.FDA - HEALTH CARE PROFESSIONALS SHOULD ALSO BE VIGILANT IN MONITORING FOR DIFFERENTIATION SYNDROME WHEN PRESCRIBING AGIOS' TIBSOVO.  Full Article

Agios Pharmaceuticals - Co, Celgene Agreed To Terminate Collaboration, License Deal
Wednesday, 5 Sep 2018 

Sept 5 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS PHARMACEUTICALS INC - ON SEPT 4, CO, CELGENE AGREED TO TERMINATE COLLABORATION AND LICENSE DEAL DATED APRIL 27, 2015 BETWEEN CO AND CELGENE.AGIOS PHARMA- FOR SPECIFIED PERIOD CELGENE SHALL BE PROHIBITED FROM DEVELOPING, COMMERCIALIZING PRODUCT THAT INHIBITS ISOCITRATE DEHYDROGENASE 1.AGIOS - ON SEPT 4, CO, CELGENE ALSO AGREED TO TERMINATE LICENSE AGREEMENT DATED APRIL 27, 2015 BETWEEN CO'S UNIT AND CELGENE INTERNATIONAL II SARL.AGIOS PHARMACEUTICALS INC - PROHIBITED PRODUCTS APPLY FOR INHIBITS ISOCITRATE DEHYDROGENASE 1 AT SPECIFIED LEVELS OF BINDING FOR ANY INDICATION.AGIOS PHARMACEUTICALS INC - COMPANY SHALL BE PROHIBITED FROM DEVELOPING, MANUFACTURING OR COMMERCIALIZING AG-881 IN HEMATOLOGIC INDICATIONS.AGIOS PHARMACEUTICALS - FROM & AFTER AG-881 AGREEMENT TERMINATION DATE, CO TO OBTAIN SOLE GLOBAL RIGHTS TO AG-881 - SEC FILING.AGIOS PHARMACEUTICALS - NO PARTY TO HAVE FINANCIAL OBLIGATION TO OTHER PARTIES, INCLUDING MILESTONES, ROYALTIES, OTHER PAYMENTS AFTER TERMINATION DATE.  Full Article

Agios Announces Chief Executive Officer Succession Plan
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES CHIEF EXECUTIVE OFFICER SUCCESSION PLAN.AGIOS PHARMACEUTICALS SAYS CURRENT CEO DAVID SCHENKEIN TO BECOME EXECUTIVE CHAIRMAN, EFFECTIVE FEB 1, 2019.AGIOS PHARMACEUTICALS SAYS JACQUALYN FOUSE TO SUCCEED SCHENKEIN AS CEO; FOUSE WILL REMAIN MEMBER OF BOARD.AGIOS PHARMACEUTICALS SAYS CURRENT CHAIRMAN JOHN MARAGANORE WILL TRANSITION TO DIRECTOR OF BOARD, EFFECTIVE FEB 1, 2019.  Full Article

Agios Q2 Revenue $40.4 Million
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $40.4 MILLION.Q2 REVENUE VIEW $11.3 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $1.19.  Full Article

FDA Says Tibsovo's Prescribing Information Includes Boxed Warning Regarding Differentiation Syndrome
Friday, 20 Jul 2018 

July 20 (Reuters) - U.S. Food and Drug Administration::FDA SAYS TIBSOVO'S PRESCRIBING INFORMATION INCLUDES BOXED WARNING THAT A POTENTIALLY FATAL ADVERSE REACTION KNOWN AS DIFFERENTIATION SYNDROME CAN OCCUR.  Full Article

Agios Pharmaceuticals Says FDA Grants Approval Of Tibsovo
Friday, 20 Jul 2018 

July 20 (Reuters) - Agios Pharmaceuticals Inc ::FDA GRANTS APPROVAL OF TIBSOVO®, THE FIRST ORAL, TARGETED THERAPY FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND AN IDH1 MUTATION.AGIOS PHARMACEUTICALS - TIBSOVO, AN ORAL, TARGETED INHIBITOR OF IDH1 ENZYME, IS FIRST FDA-APPROVED THERAPY FOR PATIENTS WITH R/R AML & AN IDH1 MUTATION.  Full Article

Agios Announces Proposed Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING.SAYS ALL OF SHARES IN OFFERING ARE TO BE SOLD BY AGIOS.  Full Article

Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agios Pharmaceuticals Inc ::AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE.AGIOS PHARMACEUTICALS INC - SEVENTH IND SUBMISSION FOR A DHODH INHIBITOR FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES EXPECTED IN 4Q 2018.AGIOS - 2017 YEAR END CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES OF $568M FUNDS EXPANDED CLINICAL & RESEARCH PROGRAMS THROUGH END OF 3Q 2019.AGIOS PHARMACEUTICALS INC - TWO PIVOTAL TRIALS IN PYRUVATE KINASE DEFICIENCY WITH AG-348, ACTIVATE-T TO INITIATE IN 1Q 2018 AND ACTIVATE IN 2Q 2018.AGIOS PHARMACEUTICALS INC - PHASE 2 PROOF OF CONCEPT TRIAL OF AG-348 IN THALASSEMIA PLANNED FOR 4Q 2018.AGIOS PHARMACEUTICALS INC - MAT2A INHIBITOR AG-270 EXPECTED TO ENTER PHASE 1 DOSE-ESCALATION TRIAL IN MTAP-DELETED TUMORS IN 1Q 2018.  Full Article